Head, Immunogenomics Core
Brian Abel received his Ph.D. in 2006 at the ETH, Zurich, and thereafter conducted a postdoctoral fellowship at SATVI, University of Cape Town, where he oversaw the immunological assessment of a novel TB vaccine in clinical trials and contributed to TB biomarker discovery. Brian completed an MBA at Tel Aviv University and ISB, Hyderabad, to facilitate a transition from academia into translational roles in biomedical science. Brian joined SIgN in 2012 to manage the Immunomonitoring Platform, conducting business development, project management and supporting finalization of agreements with industry partners, as well as acquiring regulatory approval for clinical research. He is also actively involved in Platform technology development in order to keep it up to date with the latest advances in the field of Immunomonitoring. In August 2016, Brian became the Head of the Immunogenomics Core to support and drive genomic activities for SIgN's researchers and facilitate collaborations with industry partners.
He is actively involved in Platform technology development in order to keep it up to date with the latest advances in the field of Immunomonitoring.